Trial
NCT03557970
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
OHSU Knight Cancer Institute
Collaborators
Oregon Health and Science University; Janssen, LP; The Leukemia and Lymphoma Society
Condition
Recurrent Acute Myeloid Leukemia
Intervention
Edicotinib
Why stopped
Not enough enrollment to determine efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-12-02